Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M

PUMA BIOTECHNOLOGY, INC.

2025-Q1 EPS reported $0.06 revenue$46,007,000

GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.
Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.
Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.
Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.
Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.